Gland Pharma Q2 FY25: The generic injectable-focused company's consolidated net profit declined to Rs 163.5 crore in Q2 FY25 from Rs 194 crore in the year-ago period. Consolidated revenue, however, increased 2 per cent year-on-year (YoY) to Rs 1,405.8 crore.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.